Back to top
more

Adherex Technologies (FENC)

(Delayed Data from NSDQ)

$8.17 USD

8.17
74,223

-0.15 (-1.80%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $8.16 -0.01 (-0.12%) 7:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?

by Zacks Equity Research

Here is how Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Zacks Equity Research

Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why

by Zacks Equity Research

Adherex Technologies (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

The Joint Misses Q1 Earnings Estimates on Rising Expenses

by Zacks Equity Research

JYNT expects to open 30-40 franchised clinics in 2025, down from 57 last year.

Zacks Equity Research

Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions

by Zacks Equity Research

ACHC continues to witness growth in patient days. It authorizes a share repurchase program of almost $300 million.

Zacks Equity Research

Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of 66.67% and 9.32%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of -21.43% and 78.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 11.76% and 49.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Adherex Technologies (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Adherex Technologies (FENC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?

by Zacks Equity Research

Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -110.71% and 73.17%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is the Options Market Predicting a Spike in Adherex Technologies (FENC) Stock?

by Zacks Equity Research

Investors need to pay close attention to Adherex Technologies (FENC) stock based on the movements in the options market lately.

Zacks Equity Research

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -61.54% and 23.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -42.79% and 26.90%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Denali Therapeutics (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -433.33% and 46.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -142.86% and 3.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -26.09% and 5.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 16.67% and 9.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Implied Volatility Surging for Fennec (FENC) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Fennec (FENC) stock based on the movements in the options market lately.

Zacks Equity Research

Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -16.33% and 142.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 1.74% and 223.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?